MeiraGTx Holdings (MGTX) Shares Outstanding (Weighted Average) (2017 - 2025)
MeiraGTx Holdings (MGTX) reported Shares Outstanding (Weighted Average) of $80.4 million for Q4 2025, up 15.19% on a YoY basis from $69.8 million in Q4 2024, and little changed quarter-over-quarter from $80.2 million in Q3 2025.
MeiraGTx Holdings (MGTX) Shares Outstanding (Weighted Average) (2017 - 2025) Analysis & Trends
MeiraGTx Holdings has reported Shares Outstanding (Weighted Average) for 9 years, with the latest figure at $80.4 million in Q4 2025.
- For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 15.19% year-over-year to $80.4 million; the trailing twelve-month figure through Dec 2025 stood at $80.4 million (up 15.19% YoY), and the FY2025 full-year result was $80.4 million, up 15.19% from the prior year.
- Shares Outstanding (Weighted Average) for Q4 2025 stood at $80.4 million, roughly flat from $80.2 million in the prior quarter.
- The five-year high for Shares Outstanding (Weighted Average) was $80.4 million in Q4 2025, with the low at $44.0 million in Q1 2021.
- Historically, Shares Outstanding (Weighted Average) has averaged $57.6 million across 5 years, with a median of $53.3 million in 2023.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Weighted Average) gained 1.17% — and 2024, when it jumped 31.72%.
- MeiraGTx Holdings' Shares Outstanding (Weighted Average) stood at $44.1 million in 2021, then rose by 2.35% to $45.2 million in 2022, then increased by 25.03% to $56.5 million in 2023, then climbed by 23.61% to $69.8 million in 2024, then gained by 15.19% to $80.4 million in 2025.
- The last three Shares Outstanding (Weighted Average) figures came in at $80.4 million (Q4 2025), $80.2 million (Q3 2025), and $79.8 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 185,491.37 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 400.00 Bn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 100.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 417.01 Bn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 68.88 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 254.10 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 928.40 Mn |
| 10 | MeiraGTx Holdings | 910.47 Mn | 844.54 Mn | 74.89 Mn | 80.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 80.43 Mn |
| Sep 30, 2025 | 80.20 Mn |
| Jun 30, 2025 | 79.81 Mn |
| Mar 31, 2025 | 79.03 Mn |
| Dec 31, 2024 | 69.82 Mn |
| Sep 30, 2024 | 66.71 Mn |
| Jun 30, 2024 | 64.22 Mn |
| Mar 31, 2024 | 64.07 Mn |
| Dec 31, 2023 | 56.49 Mn |
| Sep 30, 2023 | 54.54 Mn |
| Jun 30, 2023 | 52.01 Mn |
| Mar 31, 2023 | 48.64 Mn |
| Dec 31, 2022 | 45.18 Mn |
| Sep 30, 2022 | 44.69 Mn |
| Jun 30, 2022 | 44.67 Mn |
| Mar 31, 2022 | 44.50 Mn |
| Dec 31, 2021 | 44.14 Mn |
| Sep 30, 2021 | 44.17 Mn |
| Jun 30, 2021 | 44.14 Mn |
| Mar 31, 2021 | 43.97 Mn |